Welcome to MolDiag-PaCa
Brown, A. et al. "Automated system for capture and detection of nucleic acids." (1999) Biotechniques. 27: 176-80. 

[1] LÜTTGES, J., GALEHDARI, H., BRÖCKER, V., SCHWARTE-WALDHOFF, I., HENNE-BRUNS, D., KLÖPPEL, G., SCHMIEGEL, W., HAHN, S.A.: Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am. J. Pathol. 158: 1677-1683 (2001)

[2] SIPOS, B., KLAPPER, W., KRUSE, M.-L., KALTHOFF, H., KERJASCHKI, D., KLÖPPEL, G.: Expression of lymphangiogenic factors and evidence of intratumoral lymphangiogenesis in pancreatic endocrine tumors. Am J Pathol 165: 1187-1197 (2004)

[3] GRÜTZMANN, R., PILARSKY, C., AMMERPOHL, O., LÜTTGES, J., BÖHME, A., SIPOS, B., FOERDER, M., ALLDINGER, I., JAHNKE, B., SCHACKERT, H.K., KALTHOFF, H., KREMER, B., KLÖPPEL, G., SAEGER, H.D.: Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia 6: 611-622 (2004)

[4] MÜERKÖSTER, S., WEGEHENKEL, K., ARLT, A., WITT, M., SIPOS, B., KRUSE, M.L., SEBENS, T., KLÖPPEL, G., KALTHOFF, H., FÖLSCH, U.R., SCHÄFER, H.: Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1β. Cancer Res 64: 1331-1337 (2004)

[5] KLÖPPEL, G., LÜTTGES, J.: The pathology of ductal-type pancreatic carcinomas and pancreatic intraepithelial neoplasia: insights for clinicians. Curr Gastroenterol Rep 6: 111-118 (2004)

(1) Guo J, Kleeff J, Li J, Ding J, Hammer J, Zhao Y, Giese T, Korc M, Buchler MW, Friess H. Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene 2004 Jan 8;23(1):71-81.

(2) Guweidhi A, Kleeff J, Giese N, Fitori JE, Ketterer K, Giese T, Buchler MW, Korc M, Friess H. Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis 2004 Sep;25(9):1575-85.

(3) Liao Q, Guo J, Kleeff J, Zimmermann A, Buchler MW, Korc M, Friess H. Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology 2003 Jun;124(7):1830-45.

(4) Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004 Mar 18;350(12):1200-10.

(5) Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004 May;91(5):586-94.

1. Huber, M., Bahr, I., Krätzschmar, J. R., Becker, A., Müller, E.-C., Donner, P., Pohlenz, H.-D., Schneider, M. R., Sommer, A. 2004: Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r. Mol Cell Proteomics 4, 43-55.

2. Sommer, A., Hoffmann, J., Lichtner, R. B., Schneider, M. R., Parczyk, K. 2003: Studies on the development of resistance to the pure antiestrogen FaslodexTM in three human breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 85, 33-47.

3. Egner U., Krätzschmar J., Kreft B., Pohlenz H.-D.-, Schneider M. 2005: The target discovery process. Chembiochem. 6, 468-479.

4. Becker, M., Sommer, A., Krätzschmar, J. R., Seidel, H., Pohlenz, H.-D., Fichtner, I. 2005: Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen resistant subline MaCa 3366/TAM. Mol Cancer Ther. 4, 151-168.

5. Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L. 1999: A high-affinity human antibody that targets tumoral blood vessels. Blood. 94, 192-198.